Skip to content

Development of an epigenetic marker panel for the classification of alcohol consumption habits

Development of an epigenetic marker panel for the classification of alcohol consumption habits - EpiMalc

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00035543
Enrollment
125
Registered
2026-01-29
Start date
2026-08-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Individual alcohol consumption habits

Interventions

Group 1: Participants with no, moderate, and high regular alcohol consumption may keep a drinking diary for six weeks (only applies to the cohort with moderate consumption) and then undergo six weeks

Sponsors

Universitätsklinikum Freiburg, Institut für Rechtsmedizin
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Written informed consent has been obtained. “Continuous” alcohol consumption behavior (according to AUDIT-C with low, moderate or high risk for classification into cohorts with no, moderate and high consumption).

Exclusion criteria

Exclusion criteria: Age <18 years, high alcohol consumption without current qualified withdrawal, current polytoxicomania, known alcohol metabolism disorder, severe acute cardiovascular, respiratory, renal or coagulation disorder requiring treatment, poor blood vessel conditions in the arms, inability to give consent.

Design outcomes

Primary

MeasureTime frame
The primary target variables of the study are DNA methylation levels and the quantity of RNAs (in connection with individual alcohol consumption and control by laboratory chemical alcohol consumption markers).

Secondary

MeasureTime frame
The secondary objective is the significance of the identified markers in the mathematical model for classifying individual alcohol consumption behavior.

Countries

Germany

Contacts

Public ContactLorenz Bell

Universitätsklinikum Freiburg, Institut für Rechtsmedizin

lorenz.bell@uniklinik-freiburg.de+49 761 270 81853

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 10, 2026